A Phase 2 interventional study of migalastat HCl in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 5 sites in United States. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-10-30.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one is the 16th largest by enrollment, is one of 4 that started in 2006, is one of 6 in phase 2, and was the 1st registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2006.
This study's enrollment of 9 is below the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
26 studies in Fabry Disease by BioMarin Pharmaceutical: 3 open now, 4 under way, 2 of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2006, is one of 6 in phase 2, and was the 1st registered.
BioMarin Pharmaceutical’s Fabry Disease studies by the year they started, since 2006.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
Among BioMarin Pharmaceutical’s 26 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
This was a Phase 2, open-label study in male participants with Fabry disease. All participants who met initial eligibility criteria underwent a 28-day screening period, including a 14-day run-in with migalastat (150 milligrams [mg] migalastat once a day [QD] from Days -28 to -15) to assess eligibility for entering the treatment period of the study. Participants who entered the treatment period were required to have α-galactosidase A (α-Gal A) activity responsive to migalastat.
Fifteen participants received at least 1 dose of study drug, however, 6 of these participants did not demonstrate α-Gal A activity responsive to migalastat and were thus screen failures (these participants are hereafter referred to as "dosed screen failures") due to not meeting all inclusion criteria for treatment. Therefore, 9 participants were enrolled into the treatment period (these participants are hereafter referred to as "eligible-enrolled").
Eligible-enrolled participants (those who satisfied the criteria for inclusion in the study) received escalating doses of migalastat twice a day (BID) for 6 weeks (Days 1 to 42), followed by 6 weeks at 1 dose level BID (Days 43 to 84) during the treatment period. Participants could then opt to participate in the extension period. The study consisted of 2 optional extension periods, the first through Week 48 and the second through Week 96. For participants who did not continue into the optional treatment extension, the study included a 2-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Migalastat was administered orally during the 12-week treatment period and then during the optional 2 treatment extension periods. Treatment Period: * Migalastat 25 mg BID for Weeks 1 and 2 (Day 1 through the morning dose on Day 14). * Migalastat 100 mg BID for Weeks 3 and 4 (Day 15 through the morning dose on Day 28). * Migalastat 250 mg BID for Weeks 5 and 6 (Day 29 through the morning dose on Day 42). * Migalastat 25 mg BID for Weeks 6 to 12 (Days 43 to 84). Extension Period: * Migalastat 25 mg BID for Weeks 12 through 48. * Migalastat 50 mg QD for Weeks 48 through 96.
Drug: migalastat HCl
Also known as: AT1001, Galafold, migalastat
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 96 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Day 1 (after dosing) through Week 96
PK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat
The AUC from time zero to 12 hours (hr) postdose (AUC0-12) was evaluated in plasma following a single dose of migalastat 25, 100, and 250 mg on Days 1, 15, and 29, respectively. In addition, AUC0-12 was assessed following multiple doses (14 days) of migalastat 25, 100, and 250 mg on Days 14, 28, and 42, respectively.
Time frame: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, and 10 hr (postdose)
α-Galactosidase A (α-Gal A) Activity In Leukocytes At Baseline, Week 12, And Week 96
Leukocytes were isolated from whole blood and lysed, and α-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole \[nmol\] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. α-Gal A activity in leukocytes are presented by individual participants.
Time frame: Baseline, Week 12 (end of treatment period), Week 96 (end of extension period)
| Milestone | Migalastat |
|---|---|
| Started | 9 |
| Safety population | 9 |
| Pharmacokinetic (pk) population | 9 |
| Pharmacodynamic (pd) population | 9 |
| Completed | 8 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | Migalastat |
|---|---|
| Started | 8 |
| Completed | 6 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 2 |
TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 96 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Participants | Migalastat |
|---|---|
| Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) | 2 |
The AUC from time zero to 12 hours (hr) postdose (AUC0-12) was evaluated in plasma following a single dose of migalastat 25, 100, and 250 mg on Days 1, 15, and 29, respectively. In addition, AUC0-12 was assessed following multiple doses (14 days) of migalastat 25, 100, and 250 mg on Days 14, 28, and 42, respectively.
| nanograms*hr/milliliters (ng*hr/mL) | Migalastat 25 mg | Migalastat 100 mg | Migalastat 250 mg |
|---|---|---|---|
| AUC0-12: Single Dose | 1052.96 ± 29.9 | 4217.95 ± 32.0 | 10880.66 ± 32.4 |
| AUC0-12: Multiple Dose | 1360.69 ± 32.9 | 5643.50 ± 25.3 | 12244.47 ± 26.0 |
Leukocytes were isolated from whole blood and lysed, and α-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole \[nmol\] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. α-Gal A activity in leukocytes are presented by individual participants.
| nmol 4-MU/hr/mg protein | Migalastat |
|---|---|
| Participant 1: Baseline | 5.2 |
| Participant 1: Week 12 | 17.4 |
| Participant 1: Week 96 | 20.3 |
| Participant 2: Baseline | 4.7 |
| Participant 2: Week 12 | 24.6 |
| Participant 2: Week 96 | 22.8 |
| Participant 3: Baseline | 6.6 |
| Participant 3: Week 12 | 24.6 |
| Participant 3: Week 96 | 20.3 |
| Participant 4: Baseline | 1.0 |
| Participant 4: Week 12 | 14.8 |
| Participant 4: Week 96 | 12.8 |
| Participant 5: Baseline | 10.7 |
| Participant 6: Baseline | 0.9 |
| Participant 6: Week 12 | 3.9 |
| Participant 6: Week 96 | 1.9 |
| Participant 7: Baseline | 0.0 |
| Participant 7: Week 12 | 0.4 |
| Participant 8: Baseline | 0.1 |
| Participant 8: Week 12 | 0.9 |
| Participant 9: Baseline | 0.2 |
| Participant 9: Week 12 | 0.3 |
| Participant 9: Week 96 | 0.2 |
Collected over Day 1 after dosing through Week 96 (end of extension period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Migalastat | — | 0/9 (0%) | 9/9 (100%) |
| Event | Migalastat |
|---|---|
| HeadacheNervous system disorders | 5/9 |
| NauseaGastrointestinal disorders | 4/9 |
| Abdominal pain upperGastrointestinal disorders | 2/9 |
| Back painMusculoskeletal and connective tissue disorders | 2/9 |
| DiarrhoeaGastrointestinal disorders | 2/9 |
| Dry mouthGastrointestinal disorders | 2/9 |
| InsomniaPsychiatric disorders | 2/9 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/9 |
| PainGeneral disorders | 2/9 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/9 |
Eligible-enrolled participants who received at least 1 dose of study drug. 6 participants were dosed screen failures, and were not included in safety, PK, or PD analyses.
| Age, Continuous(years) | Migalastat |
|---|---|
| Mean | 36.7 ± 13.0 |
| Age, Customized(Participants) | Migalastat |
|---|---|
| 17 years | 1 |
| 18 to 55 years | 7 |
| 58 years | 1 |
| Sex: Female, Male(Participants) | Migalastat |
|---|---|
| Female | 0 |
| Male | 9 |
Ran from Jan 2006 to primary completion in Jan 2008, 24 months.
Results were first posted in Sep 2018, 10 years 7 months after primary completion. A results delay was requested in Aug 2010.
Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's 24 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat